Arcutis Biotherapeutics (ARQT) vs IDEAYA Biosciences (IDYA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
IDEAYA Biosciences (IDYA) has outperformed Arcutis Biotherapeutics (ARQT) over the past year, gaining 34.4% versus a gain of 15.3%. Over five years, IDYA leads with a +55.9% price change compared with +9.9% for ARQT. IDEAYA Biosciences is the larger company by market cap ($3.50 billion vs $3.32 billion), about 1.1 times the size.
Arcutis Biotherapeutics converts more of its revenue into profit, with a net margin of -4.3% versus -52.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARQT | IDYA |
|---|---|---|
| Share price | $26.38 | $36.28 |
| Market cap | $3.32B | $3.50B |
| 1-day change | +7.70% | +0.61% |
| YTD return | -15.67% | +4.31% |
| 1-year return | +15.30% | +34.35% |
| 5-year return | +9.92% | +55.90% |
| P/E ratio (TTM) | 119.89 | — |
| Forward P/E | 19.39 | — |
| EPS (TTM) | $0.22 | $-1.94 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $376.07M | $218.71M |
| Revenue growth (YoY) | +91.34% | +3024.43% |
| Net income (latest FY) | $-16.14M | $-113.70M |
| Gross margin | 90.24% | — |
| Operating margin | -3.25% | -72.84% |
| Net margin | -4.29% | -51.99% |
| 52-week high | $31.77 | $42.68 |
| 52-week low | $19.30 | $26.05 |
| Distance from 52-week high | -16.98% | -15.00% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +40.28% | +45.40% |
| Average volume | 2.23M | 779.15K |
| Shares outstanding | 125.69M | 96.49M |
| Employees | 354 | 145 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IDYA has outperformed ARQT by 19.1 percentage points over the past year.
- Arcutis Biotherapeutics is more profitable, keeping -4.3 cents of every revenue dollar as net income versus -52.0 cents for IDEAYA Biosciences.
- IDEAYA Biosciences grew revenue faster in its latest fiscal year (+3024.43% vs +91.34%).
About Arcutis Biotherapeutics
ARQT stock →Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis.
Health Care · Biotechnology: Pharmaceutical Preparations · 354 employees
About IDEAYA Biosciences
IDYA stock →IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase, C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer, and is being evaluated in multiple clinical trials as monotherapy and in combination with crizotinib for metastatic, neoadjuvant, and adjuvant settings.
Health Care · Biotechnology: Pharmaceutical Preparations · 145 employees
ARQT vs IDYA FAQ
Which is bigger, Arcutis Biotherapeutics or IDEAYA Biosciences?
IDEAYA Biosciences (IDYA) is larger, with a market capitalization of $3.50B compared with $3.32B for Arcutis Biotherapeutics (ARQT).
Which stock has performed better over the past year, ARQT or IDYA?
IDYA returned +34.35% over the past 12 months, compared with +15.30% for ARQT (price return, excluding dividends). Past performance does not predict future results.
Are Arcutis Biotherapeutics and IDEAYA Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.